Cintia Piccina - Net Worth and Insider Trading
Cintia Piccina Net Worth
The estimated net worth of Cintia Piccina is at least $27,598 dollars as of 2024-12-01. Cintia Piccina is the Chief Commercial Officer of Adaptimmune Therapeutics PLC and owns about 38,293 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $27,598. Details can be seen in Cintia Piccina's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Cintia Piccina has not made any transactions after 2024-06-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Cintia Piccina
Cintia Piccina Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Cintia Piccina owns 2 companies in total, including Adaptimmune Therapeutics PLC (ADAP) , and AlloVir Inc (ALVR) .
Click here to see the complete history of Cintia Piccina’s form 4 insider trades.
Insider Ownership Summary of Cintia Piccina
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | 2024-06-18 | Chief Commercial Officer |
| ALVR | AlloVir Inc | 2023-06-12 | Chief Commercial Officer |
Cintia Piccina Latest Holdings Summary
Cintia Piccina currently owns a total of 1 stock. Cintia Piccina owns 38,293 shares of Adaptimmune Therapeutics PLC (ADAP) as of June 18, 2024, with a value of $27,598.
Latest Holdings of Cintia Piccina
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | 2024-06-18 | 38,293 | 0.72 | 27,598 |
Holding Weightings of Cintia Piccina
Cintia Piccina Form 4 Trading Tracker
According to the SEC Form 4 filings, Cintia Piccina has made a total of 3 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Adaptimmune Therapeutics PLC is the sale of 24,531 shares on June 18, 2024, which brought Cintia Piccina around $22,814.
Insider Trading History of Cintia Piccina
- 1
Cintia Piccina Trading Performance
Cintia Piccina Ownership Network
Cintia Piccina Owned Company Details
What does Adaptimmune Therapeutics PLC do?
Who are the key executives at Adaptimmune Therapeutics PLC?
Cintia Piccina is the Chief Commercial Officer of Adaptimmune Therapeutics PLC. Other key executives at Adaptimmune Therapeutics PLC include Chief Medical Officer Elliot Norry , Chief Operating Officer Bertrand William C Jr , and Chief Patient Supply Officer John Lunger .
Adaptimmune Therapeutics PLC (ADAP) Insider Trades Summary
Over the past 18 months, Cintia Piccina made 1 insider transaction in Adaptimmune Therapeutics PLC (ADAP) with a net sale of 24,531. Other recent insider transactions involving Adaptimmune Therapeutics PLC (ADAP) include a net sale of 73,322 shares made by Adrian Rawcliffe , a net sale of 35,120 shares made by John Lunger , and a net sale of 32,818 shares made by Bertrand William C Jr .
In summary, during the past 3 months, insiders sold 0 shares of Adaptimmune Therapeutics PLC (ADAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 245,864 shares of Adaptimmune Therapeutics PLC (ADAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 245,864 shares.
Adaptimmune Therapeutics PLC (ADAP)'s detailed insider trading history can be found in Insider Trading Tracker table.
Adaptimmune Therapeutics PLC Insider Transactions
Cintia Piccina Mailing Address
Above is the net worth, insider trading, and ownership report for Cintia Piccina. You might contact Cintia Piccina via mailing address: 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire X0 X0 Ox14 4r.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
